Case Presentation 1 Copd
Case Presentation 1 Copd
Case Presentation 1 Copd
CASE
PRESENTATION
ON
COPD
SUBMITTED TO : SUBMITTED BY :
SUBMISSION DATE
HISTORY-TAKING
&
PHYSICAL-
EXAMINATION
DEMOGRAPHIC DATA:
SEX :-MALE
IP NUMBER :-48967
EDUCATION : - ILLITERATE
OCCUPATION : - SHOPKEEPER
INCOME :-10000/MONTH
RELIGION :-HINDU
MOTHER TONGUE:-MARATHI
DIAGNOSIS :- COPD
HISTORY-TAKING
CHIEF COMPLIANTS:-
PATIENT WAS APPARENTLY ALRIGHT 15 DAYS BACK THEN DEVELOPED MILD, WHICH WAS REMAIN
UNTREATED AND PROGRESSIVLY CHANGED IN SEVER COUGH WITH EXPECTORATION, BREATHLESSNESS
WHICH IS MORE IN SUPINE POSITION. THE EXPECTORANT IS WHITE COLOUR AND MUCOID IN NATURE.
HE HAS SHOWN TO ONE LOCAL DOCTOR. FROM THERE HE IS REFERRED HERE FOR FURTHER
TREATMENT.
MEDICAL HISTORY: -PATIENT IS A KNOWN CASE OF BRONCHIAL ASTHEMA SINCE 5 YEARS, NOT ON
REGALAR TREATMENT WITH TAB ASTHALIN 50 MG.
FAMILY HISTORY:-
PERSONAL HISTORY:-
BOWEL AND BLADDER HABITS: BOWEL AND BLADDER MOVEMENT ARE NORMAL.
PHYSICAL EXAMINATION
GENERAL APPEARANCE:
POSTURE : NORMAL
SKIN AND HAIR : FAIR COMPLEX, BLUISH DISCOLORATION AND NO PEDICULI IN THE HAIR.
WEIGHT : 65kgs.
VITAL SIGNS:
TEMPERATURE : 99.4F
RESPIRATION : 26/MINUTE
FACE: SYMMETRICAL
EYES:
EYEBROWS: SYMMETRICAL
CONJUNCTIVA:NO INFECTIONS
SCLERA:WHITE
LENS: DILATED
VISION:PATIENT HAS GOOD VISUAL CAPACITY; HE CAN READ AND SAW EASILY.
EARS:
RINNIE TEST- SOUND CONDUCTED BY AIR IS HEARD IS MORE SOUND CONDUCTED BY BONE.AIR
CONDUCTION IS MORE THAN BONE CONDUCTION.
NOSE:-
PATENCY –PATENT
TASTE –GOOD
NECK:
THYROID GLAND- LOBES ARE SMOOTH, SMALL, CENTRALLY LOCATED AND PAINLESS RISE FREELY WITH
SWALLOWING
INSPECTION:-NOT APPLICABLE
PALPATION:-NOT APPLICABLE
CHEST:
INSPECTION:-NO ANY TENDER SCAR, MASS, NODE PRESENT, USE OF ASSESSORY MUSCLS
FOR BREATHING.
CARDIOVASCULAR SYSTEM:-
BLADDER: - NO DISTENTION
GENITALS AREA:
MUSCULOSKELETAL SYSTEM:
NERVOUS SYSTEM:-
CRANIAL NERVES:- PRESENT THE SENSORY AND MOTOR RESPONSE OF THE NERVES.
DEEP TENDON REFLEX: - DEEP TENDON REFLEX PRESENT, BICEP’S, TRICEPS, PATELLAR, BRACHIO-
RADIALIS ETC.
SUPERFICIAL SENSORY REFLEX:-THE REFLEXS ARE REACTIVE TO LIGHT, PAIN, VIBRATION, AND TOUCH.
INVESTIGATION:-
LFT
SR.BILURUBINE
TOTAL 0.8 0.2-1.0 gm%
DIERECT 0.2 0-0.3gm% NORMAL
SR.PROTIEN 6.6 6-8 GM%
ALBUMIN 3.8 3.5-4.5 GM%
GLOBULIN 2.8 2-3.5 GM%
SGPT 18 0-40
SGOT 53 18-112
SERUM
ELECTROLYTE
RFT
BLOOD UREA 30 mg% 15-50mg% NORMAL
DISEASE
CONDITION
INTRODUCTION:
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IS A PREVENTABLE AND TREATABLE
DISEASE STATE CHARACTERISED BY AIRFLOW LIMITATION THAT IS NOT FULLY REVERSIBLE. THE
AIRFLOW LIMITATION IS USUALLY PROGRESSIVE AND ASSOCIATED WITH AN ABNORMAL
INFLAMMATORY RESPONSE OF THE LUNGS TO NOXIOUS PARTICLES OR GASES, PRIMARILY
CAUSED BY CIGARETTE SMOKING.SOME CLINICIANS CONSIDER ASTHMA AS PART OF COPD, BUT
DUE TO ITS REVERSIBILITY, IT IS CONSIDERED BY MOST TO BE A SEPARATE ENTITY.
COPD MAY INCLUDE DISEASES THAT CAUSE AIRFLOW OBSTRUCTION (EG, EMPHYSEMA,
CHRONIC BRONCHITIS) OR A COMBINATION OF THESE DISORDERS. OTHER DISEASES SUCH AS
CYSTIC FIBROSIS, BRONCHIECTASIS, AND ASTHMA WERE PREVIOUSLY CLASSIFIED AS TYPES OF
CHRONIC OBSTRUCTIVE LUNG DISEASE. HOWEVER, ASTHMA IS NOW CONSIDERED A SEPARATE
DISORDER AND IS CLASSIFIED AS AN ABNORMAL AIRWAY CONDITION CHARACTERIZED
PRIMARILY BY REVERSIBLE INFLAMMATION. COPD CAN COEXIST WITH ASTHMA. BOTH OF
THESE DISEASES HAVE THE SAME MAJOR SYMPTOMS; HOWEVER, SYMPTOMS ARE GENERALLY
MORE VARIABLE IN ASTHMA THAN IN COPD.
LUNGS LIE ON EACH SIDE OF THE MIDLINE IN THE THORACIC CAVITY. THEY ARE CONE
SHAPED & HAVE AN APEX, A BASE, COSTAL SURFACE & MEDIAL SURFACE.
THE RIGHT LUNG IS DIVIDED INTO THREE DISTINCT LOBES & THE LEFT LUNG HAS TWO LOBES.
PLEURAL SPACE IS THE SPACE BETWEEN THE INNER & OUTER LAYER OF PLEURA WHICH
NORMALLY CONTAINS A SMALL VOLUME OF LUBRICATING FLUID TO ALLOW THE LUNGS TO
EXPAND WITHOUT FRICTION.
THE INTERIOR OF THE LUNGS ARE COMPOSED OF THE BRONCHI & SMALLER AIR PASSAGE,
ALVEOLI, CONNECTIVE TISSUE, BLOOD VESSELS, LYMPH VESSELS & NERVES, ALL EMBEDDED IN
AN ELASTIC CONNECTIVE TISSUE MATRIX.
EACH LOBE IS MADE UP OF A LARGE NUMBER OF LOBULES. EACH LOBULE IS SUPPLIED WITH AIR
BY A TERMINAL BRONCHIOLE, WHICH FURTHER SUBDIVIDES INTO RESPIRATORY BRONCHIOLES,
ALVEOLAR DUCTS, & LARGE NUMBERS OF ALVEOLI (AIR SACS) THERE ARE ABOUT 150 MILLION
ALVEOLI IN THE ADULT LUNG, IN THIS STRUCTURES THAT THE PROCESS OF GAS EXCHANGE
OCCURS.
AS AIRWAYS PROGRESSIVELY DIVIDE & BECOME SMALLER AND SMALLER, THEIR WALLS BECOME
GRADUALLY THINNER UNTIL MUSCLE & CONNECTIVE TISSUE DISAPPEAR, LEAVING A SINGLE
LAYER OF SQUAMOUS EPITHELIAL CELLS IN THE ALVEOLAR DUCT & ALVEOLI.
DEFINITION:
COPD IS A DISEASE STATE CHARACTERISED BY AIRFLOW LIMITATION WHICH IS NOT FULLY
REVERSIBLE. INCLUDES CHRONIC BRONCHITIS, EMPHYSEMA AND SMALL AIRWAY DISEASE.
• IT IS CHRONIC
• IT IS PROGRESSIVE
1. CHRONIC BRONCHITIS:
2. EMPHYSEMA.
ENLARGED FROM THE LEVEL OF THE RESPIRATORY BRONCHIOLE TO THE TERMINAL BLIND
ALVEOLI. SEEN IN ALPHA 1 AT DEFICIENCY. COMMON IN LOWER LOBES
INCIDENCE:
IT IS MORE COMMON IN MEN THAN WOMEN. IT IS MORE FREQUENT IN CLIENTS LIVING IN
URBAN ENVIRONMENT AND AMONG THE SOCIEO-ECONOMICALLY DISADVANTAGES. 30% OF
SMOKERS DEVELOP COPD 20% OF ADULT MALES HAVE COPD 15% OF COPD PATIENTS ARE
SEVERELY SYMPTOMATIC 4TH LEADING CAUSE OF DEATH (USA). MORTALITY RATE STILL
RISING.INCREASE PREVALENCE IN LOW BIRTH WEIGHT AND LOW SOCIO ECONOMIC STATUS.
ABSENT
ALLERGY, AUTOIMMUNITY.
HEREDITY: ALPHA1-ANTITRYPSIN (AAT) DEFICIENCY IS A GENETICALLY DETERMINED
CAUSE OF EMPHYSEMA AND OCCASIONALLY LIVER DISEASE. ALPHA1-ANTITRYPSIN
SERVES PRIMARILY AS AN INHIBITOR OF NEUTROPHIL ELASTASE, AN ELASTIN-
DEGRADING PROTEASE RELEASED BY NEUTROPHILS. WHEN ALVEOLAR STRUCTURES ARE ABSENT
LEFT UNPROTECTED FROM EXPOSURE TO ELASTASE, PROGRESSIVE DESTRUCTION OF
ELASTIN TISSUES RESULTS IN THE DEVELOPMENT OF EMPHYSEMA. EMPHYSEMA
OCCURS BECAUSE OF AAT DEFICIENCY.
AGING: IT RESULTS IN CHANGING OF THE LUNG STRUCTURE, THE THORACIC CAGE AND
RESPIRATORY MUSCLE. AS PEOPLE AGE THERE IS GRADUAL LOSS OF RESPIRATORY PATIENT IS 65
RECOIL OF THE LUNG. THE LUNGS BECOME MORE ROUNDED AND SMALLER. THE YEARS OLD
NUMBER OF FUNCTIONAL ALVEOLI DECREASES AS A RESULT OF ALVEOLAR SUPPORTING
STRUCTURE AND LOSS OF INTRA ALVEOLAR SEPTUM, THESE CHANGES ARE SIMILAR TO
THOSE SEEN IN THE PATIENT WITH EMPHYSEMA.
PATHOPHYSIOLOGY:-
COPD
• Mucus hypersecretion
• Cilia dysfunction
• Airflow limitation
• Hyperinflexion of lungs
• Gas exchange abnormalities
• Pulmonary hypertension
• Corpulmonale
CLINICAL MANIFESTATION:-
CHRONIC BRONCHITIS
USUALLY INSIDIOUS, DEVELOPING OVER A PERIOD OF YEARS
EMPHYSEMA
GRADUAL IN ONSET AND STEADILY PROGRESSIVE
CACHEXIA ABSENT
FATIGUE PRESENT.
MANAGEMENT:
THE TREATMENT GOALS FOR COPD ARE AS FOLLOWS:
1. RISK REDUCTION:
REGARDLESS OF THE SETTING, THE NURSE HAS THE OPPORTUNITY TO TEACH THE PATIENT
ABOUT THE RISKS OF SMOKING AND THE BENEFITS OF SMOKING CESSATION.
2. OXYGENENATION:
INITIAL THERAPY SHOULD FOCUS ON MAINTAINING OXYGEN SATURATION AT 90 PERCENT
OR HIGHER. OXYGEN SUPPLEMENTATION BY NASAL CANNULA OR FACE MASK IS
FREQUENTLY REQUIRED. ADMINISTERING SUPPLEMENTAL OXYGEN RAISES THE RISK OF
PARTIAL PRESSURE OF OXYGEN.
WITH MORE SEVERE EXACERBATIONS, INTUBATION OR A POSITIVE-PRESSURE MASK
VENTILATION METHOD (E.G., CONTINUOUS POSITIVE AIRWAY PRESSURE [CPAP] IS OFTEN
NECESSARY TO PROVIDE ADEQUATE OXYGENATION).
3. BRONCHODILATORS:
BRONCHODILATORS RELIEVE BRONCHOSPASM AND REDUCE AIRWAY OBSTRUCTION BY
ALLOWING INCREASED OXYGEN DISTRIBUTION THROUGHOUT THE LUNGS AND IMPROVING
ALVEOLAR VENTILATION. THESE MEDICATIONS, WHICH ARE CENTRAL IN THE MANAGEMENT OF
COPD ARE DELIVERED THROUGH A METERED-DOSE INHALER, BY NEBULIZATION, OR VIA THE
ORAL ROUTE IN PILL OR LIQUID FORM. BRONCHODILATORS ARE OFTEN ADMINISTERED
REGULARLY THROUGHOUT THE DAY AS WELL AS ON AN AS-NEEDED BASIS. THEY MAY ALSO BE
USED PROPHYLACTICALLY TO PREVENT BREATHLESSNESS BY HAVING THE PATIENT USE THEM
BEFORE AN ACTIVITY, SUCH AS EATING OR WALKING. BRONCHODILATORS USED ARE:
4. CORTICOSTEROIDS:
A SHORT TRIAL COURSE OF ORAL CORTICOSTEROIDS MAY BE PRESCRIBED FOR PATIENTS WITH
STAGE II OR III COPD TO SEE IF PULMONARY FUNCTION IMPROVES AND SYMPTOMS DECREASE.
INHALED CORTICOSTEROIDS VIA MDI MAY ALSO BE USED. EXAMPLES OF CORTICOSTEROIDS IN
THE INHALED FORM ARE BECLOMETHASONE (BECLOVENT, VANCERIL), BUDESONIDE
(PULMICORT), FLUNISOLIDE (AEROBID), FLUTICASONE (FLOVENT), AND TRIAMCINOLONE
(AZMACORT).
FIRST-LINE ANTIBIOTICS:
ALTERNATIVE ANTIBIOTICS
ANTIPSEUDOMONAL PENICILLINS
FLUOROQUINOLONES
O2 OBTAINED FROM CYLINDERS OR WALL IS DRY. DRY O2 HAS AN IRRITATING EFFECT ON MUCUS
MEMBRABES AND DYR SECRETIONS. THEREFORE IT IS IMPORTANT TO HUMIDIFY O 2 WHEN
NEBULISATION DELIVERS PARTICULATE WATER MIST (AEROSOLS) WITH NEARLY 100% HUMIDITY.
WHEN NEBULISATION IS USED LARGE SIZE TUBING SHOULD BE USED TO CONNECT THE DEVICE
TO A FACE MASK OR T BAR.
SURGICAL MANAGEMENT:
1. BREATHING RETRAINING:
PURSED LIP BREATHING : THE PATIENT IS TAUGHT TO INHALE SLOWLY THROUGH THE
NOSE AND THEN TO EXHALE SLOWLY, THROUGH PURSED LIP, ALMOST AS IF
WHISTLING. EXHALATION SHOULD ATLEAST 3 TIMES AS LONG AS INHALATION.
DIAPHRAGMATIC BREATHING.
2. EFFECTIVE COUGHING:
THE MAIN GOAL IS TO CONSERVE ENERGY, REDUCE FATIGUE AND REMOVAL OF
SECRETION.
HUFF COUGHING
3. CHEST PHYSIOTHERAPY:
INDICATED TO THE PATIENT WITH EXCESSIVE BRONCHIAL SECRETION WITH EXPECTORATED
SPUTUM PRODUCTION GREATER THAN 25ML/DAY.EVIDENCE OF RETAINED SECRETION IN
THE PRESENCE OF ARTIFICIAL AIRWAY, LOBAR ATELECTASIS CAUSED BY MUCOUS PLUGGING.
CHEST PHYSIOTHERAPY CONSISTS OF PERCUSSION, VIBRATION AND POSTURAL DRAINAGE.
PERCUSSION AND VIBRATION ARE MANUAL OR MECHANICAL TECHNIQUES USED TO
AUGMENT POSTURAL DRAINAGE. PERCUSSION AND VIBRATION ARE USED AFTER POSTURAL
DRAINAGE TO ASSIST IN LOOSENING THE MOBILIZED SECRETION.
4. NUTRITIONAL THERAPY:
SHOULD REST AT LEAST FOR 30 MINUTES BEFORE EATING.
USE BRONCHODILATORS BEFORE MEAL AND SELECT FOOD THAT CEN BE PREPARED
IN ADVANCED.
SHOULD EAT FIVE TO SIX SMALL, FREQUENT MEAL TO AVOID FEELING OF BLOATING
AND EARLY SATIETY WHEN EATING.
FOOD THAT REQUIRE GREAT DEAL OF CHEWING SHOULD BE AVOIDED. COLD FOOD
MAY GIVE LESS OF SENSE OF A FULLNESS THAN HOT FOOD.
THEY MAY NEED 25 – 45 KCAL/KG AND1.2 -1.9G OF PROTEIN KILOGRAM TO
MAINTAIN THEIR WEIGHT.
HIGH CALORIE AND HIGH PROTEIN DIET IS RECOMMENDED.
MEGESTROL HAS BEEN USED TO STIMULATE AND INCREASE APPETITE.
FLUID INTAKE SHOULD BE AT LEAST 3L/DAY UNLESS CONTRA-INDICATED.
DRUG
STUDY
MEDICATION:-
GENITOURINARY-
VAGINAL INFLAMMATION.
NURSING
CARE -PLAN
NURSING DIAGNOSIS:
1. INEFFECTIVE AIRWAY CLEARANCE RELATED TO BRONCHO CONSTRICTION, INCREASED MUCUS PRODUCTION, INEFFECTIVE
COUGH AS EVIDENCED BY COUGH WITH SPUTUM, PRESENCE OF ABNORMAL BREATH SOUNDS, SPO2 90% WITH OXYGEN,
INCREASED RESPIRATORY RATE.
2. INEFFECTIVE BREATHING PATTERN RELATED TO CHRONIC AIRFLOW LIMITATION, ALVEOLAR HYPOVENTILATION AS EVIDENCED BY
DYSPNOEA, INCREASED RESPIRATORY RATE, DECREASED OXYGEN SATURATION.
3. IMPAIRED GAS EXCHANGE RELATED TO CHRONIC PULMONARY OBSTRUCTION, ABNORMALITIES DUE TO DESTRUCTION OF
ALVEOLAR CAPILLARY MEMBRANE AS EVIDENCED PACO2 ≥45MMHG, PAO2<60MMHG, SPO2 90%.
4. IMBALANCED NUTRITION: LESS THAN BODY REQUIREMENTS RELATED TO INCREASED WORK OF BREATHING, AIR SWALLOWING,
DEPRESSION AS EVIDENCED BY HB-7.2GM%, PALLOR OF SKIN, WEIGHT 65KG.
5. ACTIVITY INTOLERANCE RELATED TO COMPROMISED PULMONARY FUNCTION, RESULTING IN SHORTNESS OF BREATH AND
FATIGUE.
6. DISTURBED SLEEP PATTERN RELATED TO HYPOXEMIA, DYPSNEOA, COUGH, ANXIETY AND HYPERCAPNIA AS EVIDENCED BY
FREQUENT AWAKENING, PROLONGED ONSET OF SLEEP, LETHARGY.
STIMLI EFFECTORS
ADVANCED AGE-72 Y
MALE
DATE DIET MEDICATION TIME NURSING OBSERVATION NURSING CARE REMARK SIGN.
29/02/20 9am INJ.C-TRIE 1 GM, IV, 9am My patient mr.gulufdadubhaishinde, Assessed the Patient was co- SONALI
Breakfast:- BD 10, 10. 72 yr. male admitted with complaints general condition of operative
of breathlessness cough with copious the patient
POHA 1 PLATE INJ. RANTAC 50 MG
expectoration and diagnosed as
Tea-50 ml ,IV,
C.O.P.D.
TDS, 6,2,10.
DATE DIET MEDICATION TIME NURSING OBSERVATION NURSING CARE REMARK SIGN.
2/3/2020 9am INJ.C-TRIE 1 GM, IV, 9am Patient is oriented to time place, Assessed the Patient was co- SONALI
Breakfast:- BD 10, 10. person. general condition of operative
Patient is restless and looks weak. the patient
POHA 1 PLATE INJ. RANTAC 50 MG
Tea-50 ml ,IV, Patient was not slept at last night
TDS, 6,2,10. because of breathlessness & cough.
NURSE’S NOTE- 3
PATIENT NAME: - Mr. GULUF DADUBHAI SHINDE DIAGNOSIS:-CO.P.D..
AGE:- 72 YEAR D.O.A:- 28/02/2020
3/3/2020 9am INJ.C-TRIE 1 GM, IV, 9am Patient is oriented to time place, Assessed the Patient was co- SONALI
Breakfast:- BD 10, 10. person. general condition of operative
the patient
POHA 1 PLATE INJ. RANTAC 50 MG Patient was slept at last night because
Tea-50 ml ,IV, of breathlessness & cough is reduced.
TDS, 6,2,10.
Patient has activity intolerance due to
INJ. EMSET 4 MG IV dyspnea& low HB level.
TDS.6, 2, 10.
Patient’s personal hygiene is
INJ FEBRINIL 500 MG maintained
IV BD & SOS.
Patient’s appetite is improved due to
TAB FOLVIT 5 MG PO, reduction in fever.
OD, 10 AM.
PROGNOSIS NOTE:-
FIRST-DAY:-
Patients vital signs checked its tachycardia (105),trachypnoea(35),bp(100/70),and febrile
(99.4 f.).
Continuous cough with expectorant preset.
Patient looks breathless on activity, fatigue &restlessness is there due to fever.
Peripheral cyanosis is present,SPo2-82%.
ABG value shows respiratoy acidosis.
SECOND-DAY:-
THIRD DAY:-
HEALTH EDUCATION:
1. TO CONTROL COUGH AND PHLEGM
AVOID IRRITANTS TO THE LUNGS, SUCH AS CIGARETTE SMOKE, DUST, SMOG, PERFUME,
COLD AIR, AND VERY HOT AIR.
REPORT CHANGE IN COLOR, AMOUNT, OR THICKNESS OF PHLEGM THAT COULD
INDICATE AN INFECTION.
EAT SIX OR MORE SMALL MEALS AND SNACKS PER DAY RATHER THAN TWO OR THREE
LARGE MEALS.
EAT SLOWLY; PLAN AT LEAST 30 MINUTES PER MEAL. SIT FORWARD WITH ELBOWS
PROPPED ON TABLE.
UNLESS OTHERWISE DIRECTED, TRY A HIGH-PROTEIN, MODERATE-FAT, AND LOWER-
CARBOHYDRATE DIET OF SUFFICIENT CALORIES TO COVER THE INCREASED WORK OF
BREATHING.
CONSIDER A HIGH-CALORIE, HIGH-PROTEIN DRINK IF YOU DO NOT FEEL LIKE EATING.